The economic appropriateness of laboratory tests Thomas D Szucs MD MBA J R Soc Med 1997;90: [151] [152] [153] [154] While clinicians increasingly evaluate the way that they treat patients, there has been scant emphasis (particularly in Europe) on the way diagnostic tools are chosen. This means that third-party payers are often reluctant to reimburse physicians or hospitals for diagnostic tests, not because the tests are unsafe or inaccurate but simply because they are perceived to lack substantial cost-benefit. So far, there have been few well-conducted trials on the clinical and economic benefits of laboratory tests.
A good example is toxoplasmosis screening in pregnancy. Physicians want it for their patients, but in Germany (unlike France) the third-party payers have so far refused to finance the tests. There has been no comprehensive investigation to evaluate the benefits and costs of such screening.
We need to broaden the perspective of economic evaluation from treatment to diagnosis, helping clinicians to make informed choices about the best use of modern technology in patient management and disease prevention. The goal of this article is to promote discussion between providers and purchasers on the value of laboratory testing. APPROPRIATENESS Spending on laboratory tests accounts for only a small fraction of overall health care expenditure; in 1992, it was 4% of total world spending on health care products. Much of the cost of laboratory testing goes on human resources and when we examine 'invoiced laboratory product sales' (basically the cost of devices and reagents) these make up an even smaller proportion of total health care expenditure. According to a recent survey, the provision of laboratory tests was 0.9% of health care spending in France, 0.35% in Germany, 0.34% in Italy and 0.34% in the Netherlands (Arthur D, 1994, personal communication).
Health economics is as much about choice as it is about costs, and 'appropriateness' involves making the right choice of health care technology in the right patient population. In the laboratory context one measure of appropriateness is the impact that a test will have on choice of treatment. An appropriate test will usefully alter treatment or patient work-up strategy. Not to do a test in a patient who could benefit from it is just as inappropriate as to over-utilize a test in patients who will not benefit.
When analysing the economic impact of laboratory tests it is important to evaluate the total costs of the testing programme not only the costs directly related to the testing procedure (e.g. test kits, supplies, sample preparation, analysis, data management) but also those of the clinical consequences (e.g. drug therapy, isolation procedures, imaging techniques). The methodology of economic evaluation in health care is very much standardized, according to the principles of good economic practice1-3.
WHERE LABORATORY TESTS MIGHT BE USED MORE WIDELY
Laboratory tests are primarily used in diagnosis, prevention (screening) and patient management.
In diagnosis, one of the most notable recent successes of laboratory testing is in the rapid and accurate identification of pathogenic organisms. Also of increasing interest and importance is genetic testing for inherited conditions such as haemophilia, cystic fibrosis and metabolic disorders.
In prevention, tests have been developed to detect patients at high risk from a condition in which early intervention can prevent serious complications. Examples are cholesterol measurement, and screening for microalbuminuria in patients with insulin-dependent diabetes. The use of laboratory tests in patient management includes therapeutic drug monitoring in epilepsy and measurement of viral load in hepatitis C to guide interferon therapy. Future advances are likely to come from molecular biology and genetics. Much current research is focused on molecular aspects of infectious disease (eliciting resistance factors in bacteria, for example) and on genetic markers, specific areas on the DNA which encode for certain diseases. BRCAI, a susceptibility gene for breast cancer, is receiving much attention4. We are also identifying metabolic products or molecular entities associated with certain disease processes, such as cardiac troponins, which are very specific markers of myocardial cell injury. Rapid assay kits for troponin are being developed to aid the diagnosis of myocardial infarction5. At Promotion of drug utilization patterns that increase the effectiveness of health care Maximize the benefits of a drug to society Identify non-compliant patients and develop strategies to improve compliance Establish customized dosing regimens, avoiding unnecessary switches Reduce expenditure on treatment of toxic effects Substantiate need to employ certain dosages in specific patients (e.g. slow metabolizers) Enhance confidence in therapy, so increasing compliance and convenience screening to be cost-effective, leading to a reduction in hospital stay from an average of 17.6 to 13.4 days. Pharmacokinetic service direct costs were lower, averaging $7102 compared with $13 758 for controls. The researchers reported: 'The annual saving for 500 patients is $2 220 540'10.
WHO BENEFITS?
The clinical and economic benefits of the appropriate use of laboratory testing can be seen at all levels of health care.
In the laboratory, modern tests, because of their convenience and their automation, can increase efficiency and be more economic, with an increased rate of sample processing and less call on the technician's time. In the hospital there is the dual advantage of increased efficiency and a reduction in the number of patients receiving unnecessary treatment and diagnostic work-ups. In many countries physicians operate under fixed and limited budgets, so they need to know the impact of a test on the overall budget (the savings as well as the costs). Clinicians need to make a wise choice of the best mix of tests. From the public health perspective, perhaps the most important consideration is stopping the spread of disease. In tuberculosis, for example, the need is to identify patients with Mycobacterium tuberculosis as early as possible, and as specifically and sensitively as possible. Other infectious agents need to be discovered in certain high-risk groups such as prostitutes and drug abusers, because if the individuals who carry them are not identified the disease will be quickly propagated. That will specifically influence health care budgets which are not covered by third-party payers but which are usually the responsibility of the state. Third-party payers will wish to control health care costs by limiting reimbursement. They need a good understanding of economic evaluations so that they can reimburse for those tests which are cost-effective.
One major recent change is the escalation in home diagnostics for patients (for example, blood glucose levels for diabetics) and over-the-counter products such as cholesterol tests. These should reduce costs by promoting optimal drug use or early diagnosis and treatment. Patients, however, seldom have the knowledge for a rational choice of diagnostic modalities.
With regard to the patient's role in laboratory testing, we need to think about what happens when patients learn more about their health status and how it alters their way of approaching the disease. When tests are evaluated, we must look further than clinical and economic benefits and consider patient preferences too. In the future, trials of laboratory tests are likely to become more patient-oriented, rather than sample-oriented as now.
one-third of patients admitted to coronary care units have an infarction, so there is scope for a large cut in expenditure6. In cancer and cancer therapy, we are seeking mechanisms to identify the patients likely to benefit from one therapy rather than another. Further, the analysis of tumours for clonal markers can provide not only specific diagnosis but also a method of following the progression and remission of the disease7. The rationale and benefits of laboratory testing in diagnosis, prevention and patient monitoring are set out in Tables 1-3 .
EXAMPLES OF SOCIO-ECONOMIC ANALYSES
Without intervention, diabetic nephropathy develops in one-third of all patients with insulin-dependent diabetes mellitus and presents a serious threat to survival and quality of life. Microalbuminuria precedes the development of clinical diabetic nephropathy; its identification enables early protective treatment (notably with ACE-inhibitors). A joint Danish, German and British team analysed the costs and benefits of screening for, and anti-hypertensive treatment of, microalbuminuria in a simulated cohort of 8000 diabetic patients, calculating the impact of treatment at different levels of therapeutic effect. If therapy decreased the progression rate by 33%, median life expectancy would increase by 4 years. A 67% reduction in progression would increase median life expectancy to 14 years. The need for dialysis and transplantation would decrease by 21% and 63%, respectively. The researchers concluded: 'Screening and intervention programmes are likely to have life-saving effects and lead to considerable economic savings'8.
Perinatal transmission of hepatitis B is associated with considerable morbidity and mortality. To evaluate the costeffectiveness ofa routine screening programme among pregnant women and subsequent immunization of their newborn babies, an American team created a mathematical model using data from published reports and a Delphi survey on outcome probabilities and costs. The main outcome measures were the various patterns of subsequent chronic hepatitis B infection, which is especially frequent and problematic in children. They reported that, at an annual national birthrate of 3.5 million, a national policy of routine screening of all pregnant women would result in annual net savings of more than $105 million a year. Screening of high-risk groups would be less costly, and could lead to the prevention of 140 cases of acute neonatal hepatitis and 1400 cases of chronic liver disease per 100 000 pregnant women screened. The net saving would be as much as $765 million9.
In a prospective randomized study in the USA, 75 adult patients receiving aminoglycosides were followed and screened by a clinical pharmacokinetic service which made treatment recommendations. Another 70 patients, unscreened, acted as controls. The study showed 153o
